3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Colorectal Neoplasms
32
Colonic Neoplasms
8
Rectal Neoplasms
7
Neoplasm Metastasis
5
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Gallbladder Neoplasms
3
Cholangiocarcinoma
3
Neutropenia
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
mCRC
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Microsatellite-stable Colorectal Cancer
1
Lung Neoplasms
1
High-grade Extra Pulmonary Neuroendocrine Cancer
1
Gastric Cancer Adenocarcinoma Metastatic
1
First-line Treatment
1
Esophageal Squamous Cell Carcinoma
1
EFS
1
Dihydropyrimidine Dehydrogenase Deficiency
1
Clinical Stage III Gastric Cancer AJCC v8
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Carboplatin
79
pembrolizumab
64
Paclitaxel
64
Cyclophosphamide
47
Capecitabine
34
Doxorubicin
31
Taxes
28
130-nm albumin-bound paclitaxel
28
Albumin-Bound Paclitaxel
27
Gemcitabine
20
atezolizumab
18
Epirubicin
18
Cisplatin
18
Bevacizumab
18
olaparib
17
sacituzumab govitecan
15
Docetaxel
15
eribulin
14
toripalimab
13
durvalumab
13
camrelizumab
13
Drug Therapy
12
apatinib
9
Trastuzumab
9
Radiotherapy
9
Specimen Handling
8
Magnetic Resonance Spectroscopy
8
Biopsy
8
tislelizumab
7
talazoparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Triple Negative Breast Neoplasms
×
trifluridine tipiracil drug combination
×
Clear all
NCT04149444
2020-06-11
TACTIC
AHS Cancer Control Alberta
Phase 2
Withdrawn